Loading clinical trials...
Loading clinical trials...
A Phase 1 Dose-Escalation Study in Adults With Severe IgE-Mediated Food Allergy, to Assess the Safety, Tolerability, and Pharmacodynamic Effects of Short-Term Linvoseltamab Treatment, a BCMAxCD3 Bispecific Antibody to Induce T-Cell Killing of IgE Producing Plasma Cells, on Top of Chronic Dupilumab Treatment, to Prevent the Formation of New IgE Producing Plasma Cells
Conditions
Interventions
linvoseltamab
dupilumab
Locations
7
United States
University of South Florida
Tampa, Florida, United States
Emory University- Winship Cancer Institute
Atlanta, Georgia, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Clinica Universidad de Navarra - Madrid
Madrid, Spain
Start Date
May 17, 2024
Primary Completion Date
March 28, 2028
Completion Date
March 28, 2028
Last Updated
November 13, 2025
NCT03539692
NCT00267501
NCT06260956
NCT06034678
NCT06618963
NCT06930950
Lead Sponsor
Regeneron Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions